Information on EC 1.3.99.5 - 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY
1.3.99.5
-
RECOMMENDED NAME
GeneOntology No.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor)
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
a 3-oxo-5alpha-steroid + acceptor = a 3-oxo-DELTA4-steroid + reduced acceptor
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
KEGG Link
MetaCyc Link
testosterone and androsterone degradation to androstendione
-
Steroid degradation
-
Microbial metabolism in diverse environments
-
SYSTEMATIC NAME
IUBMB Comments
3-oxo-5alpha-steroid:acceptor DELTA4-oxidoreductase
A flavoprotein. This bacterial enzyme, characterized from Comamonas testosteroni, is involved in androsterone degradation. cf. EC 1.3.1.22, 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+).
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
3-keto-DELTA4-steroid-5 alpha-reductase
-
-
-
-
3-ketosteroid-DELTA4(5alpha)-dehydrogenase
-
-
-
-
3-oxo-5alpha-steroid DELTA4-dehydrogenase
-
-
-
-
3-oxo-steroid-4-ene dehydrogenase
P18405, P31213
-
3-oxo-steroid-4-ene dehydrogenase
-
-
3-oxosteroid DELTA4-dehydrogenase
-
-
-
-
4-ene-3-ketosteroid-5alpha-oxidoreductase
-
-
-
-
5 alpha-SR2
-
-
-
-
5alpha-R
-
-
5alpha-R
Rattus norvegicus Wistar
-
-
-
5alpha-R1
-
-
5alpha-reductase
-
-
5alpha-reductase
-
-
5alpha-reductase
P18405, P31213
-
5alpha-reductase
-
-
5alpha-reductase II
-
-
5alpha-reductase type 1
-
-
5alpha-reductase type 2
P31213
-
5alpha-reductase type II
P31213
-
5alpha-reductase type1
P18405
-
5alpha-reductase type2
P31213
-
5alphaR1
P18405
-
5alphaR2
P31213
-
5AR2
-
-
dehydrogenase, 3-oxo-5alphasteroid DELTA4-
-
-
-
-
DELTA4(5alpha)DH
-
-
-
-
DELTA4-3-keto steroid 5alpha-reductase
-
-
-
-
DELTA4-3-ketosteroid 5alpha-oxidoreductase
-
-
-
-
DELTA4-3-oxo steroid reductase
-
-
-
-
DELTA4-3-oxosteroid-5alpha-reductase
-
-
-
-
DELTA4-5alpha-dehydrogenase
-
-
-
-
NADPH-dependent 5alpha-reductase enzyme
-
-
r5alphaR1
-
-
S5alphaRI
-
-
S5alphaRII
-
-
S5AR
-
-
-
-
SRD5A1
-
-
SRD5A1
P18405
-
SRD5A1
C7T2J7
-
SRD5A2
-
-
SRD5A2
C7T2J8
-
SRD5A2
-
-
SRD5alpha
-
SRD5alpha enzymes form the oxidoreductase superfamily
SRD5alpha
P31213
SRD5alpha enzymes form the oxidoreductase superfamily
steroid 5-alpha reductase type 2
-
-
steroid 5-alpha-reductase
P18405, P31213
-
steroid 5alpha-reductase
-
-
-
-
steroid 5alpha-reductase
-
-
steroid 5alpha-reductase type 1
C7T2J7
-
steroid 5alpha-reductase type 1
-
-
steroid 5alpha-reductase type 2
-
-
steroid 5alpha-reductase type 2
C7T2J8
-
steroid 5alpha-reductase type II
P31213
-
steroid DELTA4-5alpha-reductase
-
-
-
-
steroid-5alpha-reductase
-
-
steroid-5alpha-reductase
P31213
-
testosterone 5alpha-reductase
-
-
-
-
type I 5alpha-reductase
P18405
-
type II 5alpha-reductase
P31213
-
CAS REGISTRY NUMBER
COMMENTARY
9036-43-5
-
ORGANISM
COMMENTARY
LITERATURE
SEQUENCE CODE
SEQUENCE DB
SOURCE
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
formerly Pseudomonas testosteroni
-
-
Manually annotated by BRENDA team
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
gene SRD5A1
UniProt
Manually annotated by BRENDA team
gene SRD5A1; gene SRD5A1
UniProt
Manually annotated by BRENDA team
gene SRD5A2
UniProt
Manually annotated by BRENDA team
gene SRD5A2; Ecuadorian population, gene SRD5A2
UniProt
Manually annotated by BRENDA team
gene SRD5A2; gene SRD5A2
UniProt
Manually annotated by BRENDA team
gene SRD5A2; isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
UniProt
Manually annotated by BRENDA team
isoforms 1 and 2
-
-
Manually annotated by BRENDA team
Korean sisters with male pseudohermaphroditism
-
-
Manually annotated by BRENDA team
patients with clinically localized prostate cancer
-
-
Manually annotated by BRENDA team
patients with hirsutism
-
-
Manually annotated by BRENDA team
patients with homocystic ovary syndrome, isoforms SRD5A1 and SRD5A2
-
-
Manually annotated by BRENDA team
patients with recurrent prostate cancer, isoforms I and II
-
-
Manually annotated by BRENDA team
recombinant isoforms I and II, expression in HEK293 cells
-
-
Manually annotated by BRENDA team
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
male B6/129 mice
-
-
Manually annotated by BRENDA team
isoforms 1 and 2
-
-
Manually annotated by BRENDA team
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
male Wistar rats, 2 isozymes 5alpha-R1 and 5alpha-R2
-
-
Manually annotated by BRENDA team
Wistar rats, 2 isozymes 5alpha-R1 and 5alpha-R2
-
-
Manually annotated by BRENDA team
isozymes SRD5alpha1, SRD5alpha2, and SRD5alpha3
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
evolution
-
steroid-5alpha-reductases, SRD5alpha, and steroid-5beta-reductase, SRD5beta, represent a convergence in evolution. Phylogenetic analysis of SRD5alpha reveals that SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group, overview. An eukaryotic ancestor likely underwent duplication events to generate these three subfamilies (type 1/2, type 3 and GPSN2 ancestors), both SRD5alpha type 1/2 and GPSN2 subfamilies may have evolved by ancient duplication events at the early stage of vertebrate and chordate evolution
evolution
P31213
steroid-5alpha-reductases, SRD5alpha, and steroid-5beta-reductase, SRD5beta, represent a convergence in evolution. Phylogenetic analysis of SRD5alpha reveals that SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group, overview. An eukaryotic ancestor likely underwent duplication events to generate these three subfamilies (type 1/2, type 3 and GPSN2 ancestors), both SRD5alpha type 1/2 and GPSN2 subfamilies may have evolved by ancient duplication events at the early stage of vertebrate and chordate evolution
metabolism
-
in vertebrates, SRD5alpha and SRD5beta are involved in C-19 and C-21 steroid biosynthesis, bile acid biosynthesis and erythropoiesis
physiological function
-
Srd5a2 catalyzes the irreversible conversion of testosterone to 5alpha-dihydrotestosterone in the male reproductive tract and is highly expressed in androgensensitive tissues such as the prostate and skin
physiological function
-
the type I enzyme is important for catabolism of excess steroids, while the type II enzyme has some role in male sexual behavior, whereas no evidence exists for it influencing female receptivity in this species. But 5alpha-reductase may play a role in regulating the effects of progesterone on female reproductive behavior. Females may have lower levels of type II than males
physiological function
C7T2J7, C7T2J8
the isozyme may play a relevant role in modulating androgen signaling in Hardarian glands; the isozyme may play a relevant role in modulating androgen signaling in Hardarian glands
physiological function
P31213
human SRD5alpha deficiencies can lead to pseudohermaphroditism, prostate cancer, polycystic ovarian syndrome and hirsutism. SRD5alpha-deficient patients exhibiting male pseudohermaphrodite phenotype lack the SRD5alpha2 isoform, but exhibited SRD5alpha1 activity
physiological function
-
Korean patients with SRD5A2 deficiency show external genitalia ranging from predominantly female to male, phenotype overview
physiological function
-
conversion of testosterone to 5alpha-dihydrotestosterone is essential for correct development of genetalia, overview
physiological function
P18405
conversion of testosterone to 5alpha-dihydrotestosterone by the enzymes 5alpha-reductase types 1, 5alphaR1, and 2, 5alphaR2, is important for normal and pathological growth of the prostate; conversion of testosterone to 5alpha-dihydrotestosterone by the enzymes 5alpha-reductase types 1, 5alphaR1, and 2, 5alphaR2, is important for normal and pathological growth of the prostate. Upregulation of 5alphaR1 enhances the cellular response to low, but not high, concentrations of testosterone. This explains one mechanism by which castration-recurrent prostate cancer can proliferate in the presence of castrate levels of circulating testosterone
physiological function
-
inhibition of 5alpha-reductase by dutasteride following castration during human LNCaP tumor regrowth in mice enhances the expression of U19/Eaf2, an androgen-regulated tumor suppressor, real-time RT-PCR expression analysis of genes in response to 5alpha-reductase inhibition, detailed overview
physiological function
P18405
a third type of 5alpha-reductase enzyme type III occurs in hormone-refractory prostate cancer cells; a third type of 5alpha-reductase enzyme type III occurs in hormone-refractory prostate cancer cells
physiological function
-
SRD5A2 and dihydrotestosterone play important roles in benign prostatic hyperplasia
metabolism
P31213
in vertebrates, SRD5alpha and SRD5beta are involved in C-19 and C-21 steroid biosynthesis, bile acid biosynthesis and erythropoiesis
additional information
-
sterol regulatory element binding proteins, SREBPs, regulate expression of Srd5a2
additional information
-
comparison of evolution, tissue distribution, enzyme characteristics and biological functions of SRD5alpha and SRD5beta, overview
additional information
P31213
comparison of evolution, tissue distribution, enzyme characteristics and biological functions of SRD5alpha and SRD5beta, overview
additional information
-
mutations of the SRD5A2 gene, e.g. Leu55Gln, cause 5alpha-reductase type 2 deficiency and masculinization defects of varying degree as a result of a prenatal lack of 5alpha-dihydrotestosterone to predominantly female phenotype newborn patient, detailed overview
additional information
P18405
prostate cancer development is accompanied by a decrease in 5alphaR2 and an increase in 5alphaR1; prostate cancer development is accompanied by a decrease in 5alphaR2 and an increase in 5alphaR1
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(5alpha)-androst-1-en-3,17-dione + oxidized dichlorophenolindophenol
1,4-androstadiene-3,17-dione + reduced dichlorophenolindophenol
show the reaction diagram
Q0S4Q9
-
-
-
?
1-androstene-3,17-dione + acceptor
1,4-androstadiene-3,17-dione + reduced reduced acceptor
show the reaction diagram
-
-
-
-
?
1-androstene-3,17-dione + phenazine methosulfate
1,4-androstadiene-3,17-dione + reduced phenazine methosulfate
show the reaction diagram
-
-
-
-
ir
1-androstene-3,17-dione + phenazine methosulfate
1,4-androstadiene-3,17-dione + reduced phenazine methosulfate
show the reaction diagram
-
acceptor: N,N,N,N-tetramethyl-1,4-phenylenediamine, menadione, phenazine methosulfate, cytochrome c
-
-
ir
1-estrene-3,17-dione + phenazine methosulfate
1,4-estradiene-3,17-dione + reduced phenazine methosulfate
show the reaction diagram
-
-
-
-
ir
5alpha-1-androsten-3,17-dione + acceptor
? + reduced acceptor
show the reaction diagram
-
acceptor: N,N,N,N-tetramethyl-1,4-phenylenediamine, menadione, phenazine methosulfate, cytochrome c
-
-
ir
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
P18405
-
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
-, 5alpha-reductase converts testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
P18405
the enzyme performs conversion of testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
5alpha-pregn-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
-, 5alpha-reductase also can act on progesterone, which is metabolized to an intermediate product that is then converted to allopregnanolone
-
-
r
deoxycorticosterone + reduced acceptor
21-hydroxy-5alpha-pregnan-3,20-dione + acceptor
show the reaction diagram
-
-
-
-
?
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
-
-
-
r
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
C7T2J7, C7T2J8
-
-
-
r
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
progesterone + reduced acceptor
pregnane-3,20-dione + acceptor
show the reaction diagram
-
-
-
-
?
testosterone + NADPH + H+
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
testosterone + NADPH + H+
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
testosterone + NADPH + H+
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
Rattus norvegicus Wistar
-
-
-
-
?
testosterone + NADPH + H+
dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
-
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
-
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
-
5alpha-dihydrotestosterone is a more potent androgen
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
testosterone i.e. 17beta-hydroxyandrost-4-en-3-one, enzyme plays a key role in androgen-dependent target tissues, where it catalyzes the conversion of testosterone to the biologically active dihydrotestosterone, transcriptional control of 5alpha-reductase expression
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
key enzyme in the degradation of steroids having an A:B ring fusion in a trans configuration
-
-
?
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
C7T2J7, C7T2J8
the isoenzyme efficiently catalyzes the in vitro transformation of testosterone into dihydrotestosterone
-
-
r
additional information
?
-
-
neonatal testicular androgens, e.g. testosterone, irreversibly program several hepatic enzyme activities in the rat including 5alpha-reductase, tissue-specific physiological regulation of isozymes
-
-
-
additional information
?
-
-
the enzyme produces precursors for the biosynthesis of allopregnenolone and tetrahydrodeoxycorticosterone, physiological role of the isozymes in the brain, overview
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
5alpha-reductase converts testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
P18405
the enzyme performs conversion of testosterone to 5alpha-dihydrotestosterone
-
-
r
5alpha-dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
5alpha-pregn-3,20-dione + NADP+
progesterone + NADPH + H+
show the reaction diagram
-
5alpha-reductase also can act on progesterone, which is metabolized to an intermediate product that is then converted to allopregnanolone
-
-
r
deoxycorticosterone + reduced acceptor
21-hydroxy-5alpha-pregnan-3,20-dione + acceptor
show the reaction diagram
-
-
-
-
?
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
-
the enzyme performs conversion of testosterone to dihydrotestosterone
-
-
r
progesterone + reduced acceptor
pregnane-3,20-dione + acceptor
show the reaction diagram
-
-
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
-
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
-
5alpha-dihydrotestosterone is a more potent androgen
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
enzyme plays a key role in androgen-dependent target tissues, where it catalyzes the conversion of testosterone to the biologically active dihydrotestosterone, transcriptional control of 5alpha-reductase expression
-
-
?
testosterone + reduced acceptor
5alpha-dihydrotestosterone + acceptor
show the reaction diagram
-
key enzyme in the degradation of steroids having an A:B ring fusion in a trans configuration
-
-
?
dihydrotestosterone + NADP+
testosterone + NADPH + H+
show the reaction diagram
C7T2J7, C7T2J8
the isoenzyme efficiently catalyzes the in vitro transformation of testosterone into dihydrotestosterone
-
-
r
additional information
?
-
-
neonatal testicular androgens, e.g. testosterone, irreversibly program several hepatic enzyme activities in the rat including 5alpha-reductase, tissue-specific physiological regulation of isozymes
-
-
-
additional information
?
-
-
the enzyme produces precursors for the biosynthesis of allopregnenolone and tetrahydrodeoxycorticosterone, physiological role of the isozymes in the brain, overview
-
-
-
COFACTOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
NADP+
C7T2J7, C7T2J8
-
NADP+
P18405
;
NADPH
C7T2J7, C7T2J8
-
NADPH
P18405
;
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
P18405
; 13.2% inhibition at 0.04 mM
(10bR)-8-chloro-4,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
;
(10bR)-8-chloro-4,5,10b-trimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
;
(10bR)-8-chloro-5,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
;
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
weak inhibition; weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazin-2(1H)-one
P18405
weak inhibition; weak inhibition
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
P18405
weak inhibition; weak inhibition
(11aR)-N,N-diethyl-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
weak inhibition; weak inhibition
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
P18405
;
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
-
(16beta)-16-bromo-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl acetate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl cyclopentylacetate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-1,4,6-trien-17-yl pentanoate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl butanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopentylacetate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl cyclopropanecarboxylate
P18405
;
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl pentanoate
-
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl phenylacetate
-
-
(16beta)-16-methylandrost-4-ene-3,17-dione
P18405
;
(16beta)-16-methylandrost-4-ene-3,17-dione
-
-
(16beta)-17-hydroxy-16-methylpregna-1,4,6-triene-3,20-dione
P18405
;
(16beta)-6-bromo-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
P18405
;
(16beta)-6-bromo-17-(hex-1-en-2-yloxy)-16-methylpregna-4,6-diene-3,20-dione
P18405
;
(16beta)-6-chloro-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
P18405
;
(16beta)-6-chloro-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
P18405
;
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
P18405
;
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one
-
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one - 3-phenyl-1,3-oxazinan-2-one (1:1)
P18405
;
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6,8-pentaene-3-carboxylic acid
P18405
;
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6-tetraene-3-carboxylic acid
P18405
;
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
;
(17beta)-17-(propan-2-ylcarbamoyl)estra-1,3,5(10)-triene-3-sulfonic acid
P18405
;
(17beta)-17-[(5S)-2-(2-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[(5S)-2-phenyl-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
P18405
;
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
P18405
;
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
P18405
;
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
P18405
;
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
P18405
;
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
P18405
;
(17beta)-2-chloro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
;
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
P18405
weak inhibitor; weak inhibitor
(17beta)-3-(hydroxymethyl)-N-(propan-2-yl)androsta-3,5-diene-17-carboxamide
-
weak inhibitor
(17beta)-3-nitro-N-(propan-2-yl)androst-3-ene-17-carboxamide
P18405
;
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
P18405
;
(17beta)-4-fluoro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
;
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
P18405
;
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
P18405
;
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
P18405
;
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
;
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
;
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
;
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
;
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
;
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
;
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
;
(20E)-20-(hydroxyimino)pregn-4-en-3-one
P18405
;
(20E)-20-(hydroxyimino)pregn-4-ene-3,6-dione
P18405
;
(20E)-20-(hydroxyimino)pregna-4,14,16-trien-3-one
P18405
;
(20E)-20-(hydroxyimino)pregna-4,16-dien-3-one
P18405
;
(21E)-21-(hydroxyimino)pregn-4-en-3-one
P18405
;
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
i.e. FCE 28260; i.e. FCE 28260
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,10a,10b,11,12,12a-dodecahydrochrysen-2-yl acetate
P18405
;
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
P18405
;
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (3-fluorophenyl)acetate
-
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl acetate
P18405
;
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl phenylacetate
-
-
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,10a,10b,11,12,12a-octahydrochrysene-1,8(2H,4bH)-dione
P18405
;
(2R,3R,10aR,12aS)-2-hydroxy-2,10a,12a-trimethyl-3-phenyl-3,4,4a,9,10,10a,10b,11,12,12a-decahydrochrysene-1,8(2H,4bH)-dione
P18405
;
(2S,9aR,11aR)-2-(4-chlorophenoxy)-5,9a,11a-trimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
P18405
;
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
P18405
;
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
P18405
;
(3beta)-6,20-dioxopregna-4,16-dien-3-yl propanoate
P18405
;
(3E,4aR,6aS,7S,11aR)-N,N-diethyl-3-(hydroxymethylidene)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4-[4-(4-bromophenoxy)benzoyl]phenyl)acetic acid
-
pH 5.5, 55% inhibition at 0.01 mM, pH 6.6, 59% inhibition at 0.01 mM
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
P18405
;
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
P18405
;
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl 4-bromobenzoate
-
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl benzoate
-
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
P18405
; 21.6% inhibition at 0.04 mM
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
i.e. LY191704; i.e. LY191704
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
;
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7E,11aR)-7-(chloromethylidene)-1,6a-dimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
i.e. azaestranone II; i.e. azaestranone II
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol 2-oxide
P18405
;
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-7-hydroxy-1,4a,6a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
-
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
;
(4aR,7S)-8-ethyl-4a,7-dimethyl-10-methylidene-7-[(2S)-3-oxobutan-2-yl]-4,4a,4b,5,6,7,8,8a,9,10-decahydrophenanthren-2(3H)-one
P18405
;
(4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol
P18405
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
;
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
;
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
;
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolin-7-ol 3-oxide
P18405
;
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
P18405
;
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
;
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
;
(4R)-5,10-seco-19-nor-pregna-4,5-diene-3,10,20-trione
P18405
a non-competitive and possibly irreversible inhibitor; a non-competitive and possibly irreversible inhibitor
(4R)-5,10-seco-estra-4,5-diene-3,10,17-trione
P18405
a non-competitive and possibly irreversible inhibitor; a non-competitive and possibly irreversible inhibitor
(5,20R)-4-diazo-21-hydroxy-20-methyl-pregn-6-en-3-one
P18405
i.e. RMI-18,341; i.e. RMI-18,341
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
P18405
;
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
-
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
P18405
;
(5aR,7aS,8S,12aR)-5a,7a-dimethyl-2-oxooctadecahydrocyclopenta[5,6]naphtho[2,1-b]azepin-8-yl acetate
P18405
;
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
;
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
;
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
;
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
;
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
;
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
P18405
;
(6aS,7S)-6a-methyl-N-(propan-2-yl)-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
P18405
-
(6aS,7S)-N,N-diethyl-6a-methyl-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
P18405
-
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
P18405
;
(6beta)-6-bromo-16-methyl-17-[(1-phenylethenyl)oxy]pregna-4,6-diene-3,20-dione
P18405
;
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
P18405
;
(7aS,8S,10aS,10bS)-N-tert-butyl-7a-methyl-2-oxo-2,3,4,5a,6,7,7a,8,9,10,10a,10b,11,12-tetradecahydrocyclopenta[f]pyrido[1,2-a]quinoline-8-carboxamide
P18405
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
;
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
;
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
P18405
;
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
P18405
;
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
;
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
P18405
;
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
-
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
P18405
;
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
-
-
1,10-phenanthroline
-
1 mM, 29% inhibition
1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
-
1,4,6-pregnatriene-3,17-dione
-
-
-
1,4-Androstadiene-3,17-dione
-
-
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
P18405
;
1-(3-carboxypropyl)-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrole-3-carboxylic acid
-
-
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
; 20% inhibition at 100 nM in transfected SW-13 cells
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
;
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
;
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
; 39.7% inhibition at 100 nM in transfected SW-13 cells; 56.3% inhibition at 100 nM in transfected SW-13 cells
1-methyl-5-phenylpiperidin-2-one
P18405
; 13.5% inhibition at 0.04 mM
1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one
P18405
61% inhibition at 0.010 mM
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
P18405
;
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
P18405
;
16,16-dimethylandrost-4-ene-3,17-dione
P18405
;
16,16-dimethylandrost-4-ene-3,17-dione
-
-
16-ethyl-17beta-hydroxy-4-estren-3-one
P18405
i.e. TSAA-291; i.e. TSAA-291
16-ethyl-17beta-hydroxy-4-estren-3-one
-
i.e. TSAA-291, with purified nuclei from rat prostatic tissues
17-(2-cyclopentylethoxy)-6-methylidenepregn-4-ene-3,20-dione
P18405
;
17-(3-cyclopentylpropoxy)-6-methylidenepregn-4-ene-3,20-dione
P18405
;
17-hydroxy-6-methylidenepregn-4-ene-3,20-dione
P18405
;
17-hydroxyestra-4,8-dien-3-one
P18405
;
17-hydroxyestra-4,9(11)-dien-3-one
P18405
;
17-hydroxypregna-4,6-diene-3,20-dione
-
-
17beta-(N-tert-butyl carbamoyl)-19-nor-10-aza-4-androsten-3-one
P18405
-
-
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
P18405
;
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
P18405
;
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
-
-
17beta-N,N-diethylcarboxy-6-azaandrost-4-en-3-one
P18405
;
-
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
P18405
;
1alpha,2alpha-epoxy-4,6-pregnadiene-3,17-dione
-
-
-
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
P18405
i.e. L612,710; i.e. L612,710
2',3'-tetrahydrofuran-2'-spiro-17-(6-methylene-4-androsten-3-one)
-
i.e. L612,710
2,2'-dipyridyl
-
1 mM, 22% inhibition
2,6,4'-methoxybenzophenone
-
from Anemarrhena aspholoides rhizomes
-
2-(trifluoromethyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
368% inhibition at 0.01 mM; 42% inhibition at 0.010 mM
2-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
138% inhibition at 0.010 mM; 166% inhibition at 0.01 mM
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
;
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
P18405
;
2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
P18405
3% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide
P18405
6% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
P18405
8% inhibition at 0.010 mM
2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide
P18405
6% inhibition at 0.010 mM
2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
P18405
43% inhibition at 0.010 mM
20-hydroxyimino-1,4-pregnadiene-3,20-dione
-
-
-
20-hydroxyimino-4-pregnene-3,20-dione
-
-
-
20-hydroxyimino-5-oxo-A-nor-3,5-secopregnan-3-oic acid
-
-
-
20-oxo-16,17-epoxypregn-5-en-3-yl acetate
P18405
;
3,20-dioxopregn-4-en-17-yl (4-bromophenyl)carbamate
P18405
;
3,20-dioxopregn-4-en-17-yl phenylcarbamate
P18405
;
3,20-dioxopregna-4,6-dien-17-yl (4-bromophenyl)carbamate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
P18405
;
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
P18405
;
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
P18405
;
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
3,20-dioxopregna-4,6-dien-17-yl phenylcarbamate
-
-
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
P18405
;
3-(2,4-dimethoxyphenyl)-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
-
3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate
P18405
33% inhibition at 0.010 mM
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
; 4.9% inhibition at 100 nM in transfected SW-13 cells
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
; 46.3% inhibition at 100 nM in transfected SW-13 cells
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino] phenoxy)benzoic acid
-
-
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
P18405
;
3-chloro-4-([1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
P18405
-
-
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
P18405
;
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
P18405
i.e. YM-36117; i.e. YM-36117
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
-
i.e. YM-36117
3-chloro-4-([1-(furan-2-ylmethyl)-2,3-dihydro-1H-indol-5-yl]oxy)benzoic acid
P18405
;
-
3-chloro-4-[(1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
-
-
3-chloro-4-[[1-(4-methoxybenzyl)-2,3-dihydro-1H-indol-5-yl]oxy]benzoic acid
P18405
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
;
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
; 48.7% inhibition at 100 nM in transfected SW-13 cells
3-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
134% inhibition at 0.01 mM; 160% inhibition at 0.010 mM
3-hydroxy-16,17-epoxypregn-5-en-20-one
P18405
;
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
P18405
;
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-4H,8H-pyrano[2,3-f]chromen-4-one
-
-
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
P18405
;
3-[2,4-bis(benzyloxy)phenyl]-5-methoxy-8,8-dimethyl-8,9-dihydro-4H,10H-pyrano[2,3-f]chromene-4,10-dione
-
-
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.00047 mM, not inhibitory to isoform 1
3-[4-(4-phenoxybenzoyl)phenyl]acrylic acid
-
pH 5.5, 63% inhibition at 0.01 mM, pH 6.6, 61% inhibition at 0.01 mM
3beta-acetoxy-20-hydroxyimino-5-pregnen-20-one
-
-
-
3beta-acetoxy-5-pregnen-20-one
-
-
-
3beta-hydroxy-20-hydroxyiminopregnenolone
-
-
-
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
P18405
;
4'-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)biphenyl-4-carboxylic acid
-
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
P18405
;
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
P18405
;
4,4a,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
4-(1-benzyl-1H-indol-5-yl)benzoic acid
P18405
;
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
P18405
;
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
-
4-(2-[[(2E)-3-[1-[bis(4-fluorophenyl)methyl]-1H-indol-5-yl]pent-2-enoyl]amino]phenoxy)butanoic acid
P18405
i.e. KF20405; i.e. KF20405
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
P18405
;
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
P18405
;
4-(4-([2,6-bis(trifluoromethyl)benzyl]oxy)benzoyl)benzoic acid
-
pH 5.5, 29% inhibition at 0.01 mM, pH 6.6, 69% inhibition at 0.01 mM
4-(4-benzoylphenoxy)benzoic acid
P18405
;
4-(4-phenoxybenzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000053 mM, not inhibitory to isoform 1
4-(4-phenoxybenzoyl)benzoic acid
-
pH 5.5, 33% inhibition at 0.01 mM, pH 6.6, 53% inhibition at 0.01 mM
4-(4-[[2,6-bis(trifluoromethyl)benzyl]oxy]benzoyl)benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000113 mM, isoform 1, 12% inhibition at 0.01 mM
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
P18405
;
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
P18405
;
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
P18405
;
4-(methoxycarbonyl)phenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
129% inhibition at 0.010 mM; 584% inhibition at 0.01 mM
4-androsten-3-one-17-carboxylic acid
P18405
competitive
-
4-aza-20-hydroxyimino-5-pregnene-3,20-dione
-
an 4-azasteroid
-
4-bromo-3,20-dioxopregn-4-en-17-yl 4-chlorobenzoate
P18405
;
4-bromo-3,20-dioxopregn-4-en-17-yl 4-fluorobenzoate
P18405
;
4-bromo-3,20-dioxopregna-1,4-dien-17-yl acetate
P18405
;
4-cyanoprogesterone
P18405
;
4-cyanoprogesterone
-
-
4-fluorophenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
119% inhibition at 0.01 mM; 93% inhibition at 0.010 mM
4-methylphenyl 4-methyl-3-oxo-2,3,5,6-tetrahydro-1H-pyrido[1,2-a]quinoline-8-carboxylate
P18405
102% inhibition at 0.010 mM; 553% inhibition at 0.01 mM
4-trifluoromethyl-N-(tert-butyl)-4-androsten-17beta-carboxamide
P18405
;
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
P18405
;
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
-
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
P18405
i.e. FR119680; i.e. FR119680
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
-
i.e. FR119680
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
P18405
;
4-[2-(1-methyl-6-oxopiperidin-3-yl)ethyl]-N,N-di(propan-2-yl)benzamide
-
-
4-[2-(5-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
P18405
;
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
P18405
;
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
-
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
P18405
;
4-[3-(1-methyl-6-oxopiperidin-3-yl)butan-2-yl]-N,N-di(propan-2-yl)benzamide
-
-
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
P18405
;
4-[3-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000131 mM, not inhibitory to isoform 1
4-[3-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, 55% inhibition at 0.01 mM, pH 6.6, 35% inhibition at 0.01 mM
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
P18405
;
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
P18405
;
4-[3-ethyl-4-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
P18405
;
4-[3-[3-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[3-[bis (4-isobutylphenyl)methyl amino] benzoyl]-lH-indol-l-yl] butyric acid
P18405
i.e. FK-143
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
P18405
i.e. FK-143
4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl] butyric acid
-
i.e. FK-143
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
P18405
-
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
-
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
P18405
;
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-1H-pyrrol-1-yl]butanoic acid
-
-
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
P18405
;
4-[3-[4-([[3-(2-methylpropyl)phenyl][4-(2-methylpropyl)phenyl]methyl]amino)benzoyl]-4-(propan-2-yl)-1H-pyrrol-1-yl]butanoic acid
-
-
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
P18405
;
4-[4-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000119 mM, not inhibitory to isoform 1
4-[4-(benzyloxy)benzoyl]benzoic acid
-
pH 5.5, 0.01 mM, 45% inhibition at 0.01 mM, pH 6.6, 64% inhibition at 0.01 mM
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
P18405
;
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
-
-
4-[4-[di(propan-2-yl)carbamoyl]-2-ethylphenyl]cyclohex-1-ene-1-carboxylic acid
P18405
;
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
P18405
;
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
P18405
;
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
P18405
;
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
P18405
;
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
P18405
;
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
type II isozyme; type I isozyme
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
P18405
;
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
-
5-(4-chlorophenyl)-1-methylpiperidin-2-one
P18405
;
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
P18405
; 14% inhibition at 0.04 mM
5-(benzyloxy)-1H-indole-2-carboxylic acid
P18405
;
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
P18405
;
5alpha,6alpha-epoxy-3beta-acetoxy-20-hydroxyiminopregnan-20-one
-
-
-
5alpha,6alpha-epoxy-3beta-acetoxypregnan-20-one
-
-
-
5alpha,6alpha-epoxy-3beta-hydroxypregnan-20-one
-
-
-
5beta,6beta-epoxy-3beta-acetoxy-20-hydroxyiminopregnan-20-one
-
-
-
5beta,6beta-epoxy-3beta-acetoxypregnan-20-one
-
-
-
6,20-dioxopregn-4-en-3-yl 4-bromobenzoate
P18405
;
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
P18405
;
6,20-dioxopregn-4-en-3-yl 5-chloropentanoate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
-
6,20-dioxopregna-4,16-dien-3-yl 4-bromobenzoate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl acetate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl acetate
-
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
P18405
;
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
-
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
6-(benzyloxy)-5-methoxy-1-methyl-1H-indole-2-carboxylic acid
P18405
;
6-([5-[(1R,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
P18405
;
6-([5-[(1S,4aR,6aR,7R,11aR)-1,4a,6a-trimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]hexanoyl]amino)hexanoic acid
P18405
;
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
P18405
i.e. ONO-3806; i.e. ONO-3806
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
P18405
;
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
P18405
;
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
P18405
;
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
-
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
P18405
;
6-hydroxy-9,10-dimethoxy-3,3-dimethyl-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(13H)-one
-
-
6-methylidene-3,20-dioxopregn-4-en-17-yl 4-bromobenzoate
P18405
;
6-[(1R,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
P18405
;
6-[(1S,4aR,6aR,7R,11aR)-7-[6-[(4-cyanobenzyl)oxy]hexan-2-yl]-4a,6a-dimethyl-1-oxidohexadecahydro-1H-indeno[5,4-f]quinolin-1-yl]hexanoic acid
P18405
;
6-[3-(N,N-dicyclohexylaminocarbonyl) phenyl]-3,4-dihydro-naphthalene-2-carboxylicacid
P18405
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
P18405
;
6-[4-(N,N-diisopropylamino-carbonyl) phenyl]naphthalene-2-carboxylic acid
P18405
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
P18405
-, uncompetitive
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-1H-quinolin-2-one
P18405
; competitive inhibitor
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-N-methyl-quinolin-2-one
P18405
;
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
P18405
;
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
;
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
P18405
;
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
;
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
P18405
-
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one8-allyl-7-hydroxycoumarin
P18405
-
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
;
8-allyl-7-hydroxycoumarin
P18405
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
-
8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
-
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-4,6-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
-
8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
8-hydroxyquinoline
-
1 mM, 10% inhibition
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
-
9,10-dihydrophenanthrene-2-carboxylic acid
P18405
;
androst-4-ene-3,17-dione
P18405
;
androst-4-ene-3,17-dione
-
-
catechin
P31213
from green tea, Camellia sinensis, is specific for SRD5alpha1 inhibition
cis-hinokiresinol
-
from Anemarrhena aspholoides rhizomes
-
CuSO4
-
1 mM, 95% inhibition
deoxycortisone
-
inhibits the synthesis of 5alpha-dihydrotestosterone by competing with 4-en-3-one function of the testosterone for the 5alpha-reductase enzyme
-
dutasteride
-
dual inhibitor for both isoform 1 and 2
dutasteride
-
inhibition of both isoform 1 and 2
dutasteride
P31213
SRD5alpha2 and SRD5alpha1 both respond similarly to dutasteride
dutasteride
P18405
inhibits 5alphaR1 and 5alphaR2; inhibits 5alphaR1 and 5alphaR2
dutasteride
-
-
dutasteride
P18405
i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration; i.e. 17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide, a competitive inhibitor of both 5alpha-reductase type I and type II isozymes, reduces DHT levels over 90% following 1 year of oral administration
EDTA
-
1 mM, 23% inhibition
epristeride
P18405
;
estra-4,8-diene-3,17-dione
P18405
;
estra-4,9(11)-diene-3,17-dione
P18405
;
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
P18405
;
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
-
finasteride
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, isoform 1, 50% inhibition at 0.051 mM
finasteride
-
pH 5.5, 50% inhibition at 0.000011 mM, pH 6.6, 50% inhibition at 0.00001 mM
finasteride
-
5mg/kg, chronic finasteride administration effectively blocks development of tolerance and dependence to morphine
finasteride
-
SRD5alpha2 is more sensitive to finasteride than SRD5alpha1
finasteride
P31213
SRD5alpha2 is more sensitive to finasteride than SRD5alpha1
finasteride
-
-
finasteride
-
both SRD5alpha subtypes 1 and 2 are inhibited
finasteride
P18405
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic DHT level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview; i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one, decreases the prostatic dihydrotestosterone level by 70-90% and reduces the prostatic size, inhibition mechanism, detailed overview
finasteride
-
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one or MK-906. A competitive inhibitor of 5alpha-reductase type II with 10fold higher affinity than type I due to formation of stable complex with enzyme
FK143
-
dual inhibitor for both isoform 1 and 2
gamma-linolenic acid
P31213
a natural product found in oil of evening primrose, Oenothera biennis, oil and borage, Borago officinalis, inhibits SRD5alpha1 and SRD5alpha2
HgCl2
-
1 mM, complete inhibition
iodoacetamide
-
1 mM, 11% inhibition
iodoacetate
-
1 mM, 8% inhibition
kaempferol
-
inhibition of both isoforms I and II
KCN
-
1 mM, 24% inhibition
linolenic acid
-
strong inhibition
mangiferin
-
a 1,3,6,7-tetrahydroxyxanthone-C2-beta-D-glucoside, from Anemarrhena aspholoides rhizomes, directly inhibits SRD5A2 binding to a complex of enzyme and substrate
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
;
methyl(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
-
MK386
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
MK906
-
significant decrease in cell proliferation of enzyme-positive prostate cancer cell lines
MnSO4
-
1 mM, 42% inhibition
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
P18405
;
N,N-dicyclohexyl-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzamide
-
-
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
i.e. PNU 157706; i.e. PNU 157706
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
;
N-(dicyclohexyl)acetyl-piperidine-4-(benzylidene-4-carboxylic acid)
P18405
;
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-cyclohexyl-N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
P18405
;
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-iodo-4-(2-methoxyquinolin-6-yl)benzamide
P18405
;
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-oxido-3-aza-1,3,5(10)-triene
P18405
;
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
P18405
;
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
P18405
;
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
;
N-tert-butyl-3-oxoestra-4,9(11)-diene-17-carboxamide
P18405
;
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
;
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
-
NaN3
-
1 mM, 26% inhibition
o-Iodosobenzoate
-
1 mM, complete inhibition
p-chloromercuribenzoate
-
1 mM, 43% inhibition
PNU157706
-
dual inhibitor for both isoform 1 and 2
pregna-4,16-diene-3,6,20-trione
P18405
;
pregna-4,16-diene-3,6,20-trione
-
-
progesterone
-
inhibits the synthesis of 5alpha-dihydrotestosterone by competing with 4-en-3-one function of the testosterone for the 5alpha-reductase enzyme
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.245 mg/ml result in 50% enzyme inhibition
-
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.385 mg/ml result in 50% enzyme inhibition
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
;
ZnSO4
-
1 mM, 53% inhibition
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphinic acid
P18405
;
[(17beta)-17-(propan-2-ylcarbamoyl)androsta-3,5-dien-3-yl]phosphonic acid
P18405
;
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000045 mM, not inhibitory to isoform 1
[3-fluoro-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 73% inhibition at 0.01 mM, pH 6.6, 57% inhibition at 0.01 mM
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000027 mM, not inhibitory to isoform 1
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 78% inhibition at 0.01 mM, pH 6.6, 50% inhibition at 0.00145 mM
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
P18405
;
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000023 mM, not inhibitory to isoform 1
[4-(4-phenoxybenzoyl)phenyl]acetic acid
-
pH 5.5, 77% inhibition at 0.01 mM, pH 6.6, 42% inhibition at 0.01 mM
[4-(4-phenoxybenzoyl)phenyl]acetic acid
P18405
;
[4-(biphenyl-4-yloxy)phenyl]acetic acid
P18405
;
[4-(biphenyl-4-yloxy)phenyl]acetic acid
-
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
-
pH 5.5, isoform 2, 50% inhibition at 0.000005 mM, not inhibitory to isoform 1
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
P18405
;
Monolinolein
-
strong inhibition
additional information
-
expression of isozyme 5alpha-R1 is inhibited by testosterone and dihydrotestosterone
-
additional information
-
screening of biologically active constituents from Brassica rapa pollen in supercritical CO2 fluid extract, overview. No inhibition by 24-methylenecholesterol linolenate, cycloeucalenol linolenate, 24-methylenecholesterol palmitate, cycloeucalenol, pollinastanol, 24-methylenecholesterol, palmitic acid, and monopalmitin
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
P31213
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
4-aza-3-oxo-1-ene compounds are the major class of synthetic SRD5alpha inhibitors, they require a structure similar to 3-oxo-4-ene with a secondary 17beta-substituent to successfully bind to the SRD5alpha-NADPH or SRD5alpha-NADP+ complexes
-
additional information
-
synthesis, enzyme inhibitory, and cell cytotoxicity of pregnan compounds, IC50 values for growth inhibition, overview
-
additional information
P18405
no inhibition of 5alphaR1 by tetracycline
-
additional information
P18405
steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. 4-Aza, 6-aza and charged 3-substituents derivatives are highly selective for type II enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, and (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one. No inhibition (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol, and by 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]-N-(prop-2-en-1-yl)acetamide, 2-[4-(1-methyl-6-oxopiperidin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 2-[4-(1,2-dimethyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)phenoxy]-N-(propan-2-yl)acetamide, 1-methyl-5-[4-(phenylacetyl)phenyl]pyridin-2(1H)-one, 2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, and 3-(2-[[16-(acetylsulfanyl)hexadecanoyl]amino]ethoxy)propyl (4Z)-6-([[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy]acetyl]amino)hex-4-enoate, as well as 8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one and 8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one; steroidal and non-steroidal 5alpha-reductase inhibitors as they inhibit the conversion of testosterone to 5alpha-dihydrotestosterone, detailed overview. Inhibitors with 4-methyl-4-aza functionality are very potent for type I enzyme. Potent inhibitors of steroid 5alpha-reductase are found among the transition state analogues as molecules mimicking the transition state of the enzymatic processes exhibit a greater binding to the enzyme and hence produce greater inhibition. The enzyme 5alpha-reductase binds the 3-keto-DELTA4 steroids in such a way that the carbonyl group is brought into vicinity of a positively charged centre on the enzyme whereby the conjugated ketone becomes activated. Poor inhibition by (4aS,6aS,7S,11aS)-7-hydroxy-4a,6a-dimethylhexadecahydro-2H-indeno[4,5-h]isoquinolin-2-one, (4aS,6aS,7S,11aS)-4a,6a-dimethylhexadecahydro-1H-indeno[4,5-h]isoquinolin-7-ol, (4aS,6aS,7S,11aR)-7-hydroxy-4a,6a-dimethyl-1,2,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-3H-indeno[5,4-f]isoquinolin-3-one, and (4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol. No inhibition by (17E)-17-(hydroxyimino)androst-5-en-3-ol, (20Z)-20-(hydroxyimino)pregn-5-en-3-ol, (20Z)-20-(hydroxyimino)pregna-5,16-dien-3-ol, 20-(hydroxyimino)pregna-5,14-dien-3-ol, and 20-(hydroxyimino)pregna-5,14,16-trien-3-ol
-
additional information
-
design and optimization of steroidal structure as 5alpha-reductase inhibitors, rationalizing the molecular properties and 5alpha-reductase inhibitory activities, three-dimensional quantitative structure-activity relationship, 3D-QSAR, study and modeling, overview
-
additional information
-
inhibitory effects on SRD5A2 of Chinese medicine herb extracts, of Anemarrhena aspholoides rhizomes, Pellodendron amurense bark, and Cinnamomum cassia bark, collected in China, Korea, and Japan, overview
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
morphine
-
morphine increases 5alpha-reductase enzyme activity in the central nervous system
testosterone
-
5alpha-reductase activity in males is increased by testosterone regardless of breeding season, thus, testosterone appears to regulate its own metabolism in male, but not female, anoles
additional information
-
testosterone stimulates the isozyme 5alpha-R1 in male rat liver
-
additional information
-
expression of isozyme 5alpha-R2 is induced by testosterone and dihydrotestosterone
-
additional information
-
no regulation of enzyme isoform I expression by 1alpha,25-dihydroxyvitamin D3
-
KM VALUE [mM]
KM VALUE [mM] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.01
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
wild-type, pH 7.4, 30C
0.066
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant W136F, pH 7.4, 30C
0.17
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant S468T, pH 7.4, 30C
0.0066
-
1-Androstene-3,17-dione
-
reaction with N,N,N,N-tetramethyl-1,4-phenylenediamine
0.000054
-
testosterone
-
pH 7.4, 37C, recombinant His-tagged enzyme
0.0004
-
testosterone
-
type II isozyme, pH not specified in the publication, temperature not specified in the publication
0.0019
-
testosterone
C7T2J7, C7T2J8
Srd5a2, pH not specified in the publication, temperature not specified in the publication
0.01
-
testosterone
-
type I isozyme, pH not specified in the publication, temperature not specified in the publication
0.0161
-
5alpha-androstane-3,17-dione
-
reaction with N,N,N,N-tetramethyl-1,4-phenylenediamine
additional information
-
additional information
P31213
under optimal conditions, SRD5alpha2 has a higher Vm/Km and a 1000fold greater affinity for steroid substrates than SRD5alpha1
-
TURNOVER NUMBER [1/s]
TURNOVER NUMBER MAXIMUM[1/s]
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.7
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant W136F, pH 7.4, 30C
1.6
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant S468T, pH 7.4, 30C
2.4
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
wild-type, pH 7.4, 30C
kcat/KM VALUE [1/mMs-1]
kcat/KM VALUE [1/mMs-1] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
9
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant S468T, pH 7.4, 30C
12254
70
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
mutant W136F, pH 7.4, 30C
12254
2400
-
(5alpha)-androst-1-en-3,17-dione
Q0S4Q9
wild-type, pH 7.4, 30C
12254
Ki VALUE [mM]
Ki VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.01
-
(10bR)-8-chloro-4,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0011
-
(10bR)-8-chloro-4,5,10b-trimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00092
-
(10bR)-8-chloro-5,10b-dimethyl-1,5,6,10b-tetrahydrophenanthridin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000036
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6,8-pentaene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00003
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4,6-tetraene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00002
-
(17beta)-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000035
-
(17beta)-2-chloro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00001
-
(17beta)-4-fluoro-17-(propan-2-ylcarbamoyl)estra-1(10),2,4-triene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00098
-
(4R)-5,10-seco-19-nor-pregna-4,5-diene-3,10,20-trione
P18405
pH not specified in the publication, temperature not specified in the publication
0.00547
-
(4R)-5,10-seco-estra-4,5-diene-3,10,17-trione
P18405
pH not specified in the publication, temperature not specified in the publication
0.000104
-
(6aS,7S)-6a-methyl-N-(propan-2-yl)-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000031
-
(6aS,7S)-N,N-diethyl-6a-methyl-5,6,6a,7,8,9,9a,9b-octahydro-4bH-indeno[5,4-f]isoquinoline-7-carboxamide 2-oxide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0016
-
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0019
-
(7-chloro-3,4,4a,9-tetrahydrophenanthren-2-yl)phosphinic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0014
-
16-ethyl-17beta-hydroxy-4-estren-3-one
-
pH not specified in the publication, temperature not specified in the publication
0.00009
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00009
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0008
-
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-1H-quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00051
-
6-[4-(N,N-diisopropylcarbamoyl) phenyl]-N-methyl-quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000026
-
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.01
-
7-bromo-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00026
-
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0012
-
7-chloro-3,4,4a,9-tetrahydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00032
-
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0025
-
7-chloro-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000315
-
9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.01
-
9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
IC50 VALUE [mM]
IC50 VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.000377
-
(10bR)-8-chloro-4,10b-dimethyl-1,4,6,10b-tetrahydrobenzo[f]quinoline-3(2H)-thione
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000002
-
(11aR)-7-(1-hydroxypropan-2-yl)-1,4a,6a-trimethyltetradecahydrocyclopenta[5,6]naphtho[2,1-d][1,3]oxazine-2(1H)-thione
P18405
pH not specified in the publication, temperature not specified in the publication
0.00000062
-
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000235
-
(16alpha,17beta)-17-hydroxy-16-methylandrost-4-en-3-one
-
pH not specified in the publication, temperature not specified in the publication
0.000000063
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
-
pH not specified in the publication, temperature not specified in the publication
0.000000079
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl butanoate
-
pH not specified in the publication, temperature not specified in the publication
0.000032
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl pentanoate
-
pH not specified in the publication, temperature not specified in the publication
0.0000012
-
(16beta)-16-methyl-3,20-dioxopregna-4,6-dien-17-yl phenylacetate
-
pH not specified in the publication, temperature not specified in the publication
0.00000052
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000048
-
(17beta)-16-ethyl-17-hydroxyandrost-4-en-3-one
-
pH not specified in the publication, temperature not specified in the publication
0.00027
-
(17beta)-17-(2-oxo-3-phenyl-1,3-oxazinan-6-yl)androst-4-en-3-one
-
37C
0.00075
-
(17beta)-17-[(5S)-2-(2-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.00105
-
(17beta)-17-[(5S)-2-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.00109
-
(17beta)-17-[(5S)-2-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.00275
-
(17beta)-17-[(5S)-2-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.00152
-
(17beta)-17-[(5S)-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.00118
-
(17beta)-17-[(5S)-2-phenyl-4,5-dihydro-1,3-oxazol-5-yl]androst-4-en-3-one
-
37C
0.0005
-
(17beta)-17-[3-(4-bromophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
37C
0.00042
-
(17beta)-17-[3-(4-chlorophenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
37C
0.000245
-
(17beta)-17-[3-(4-ethoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
37C
0.00026
-
(17beta)-17-[3-(4-ethylphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
37C
0.0006
-
(17beta)-17-[3-(4-methoxyphenyl)-2-oxo-1,3-oxazinan-6-yl]androst-4-en-3-one
-
37C
0.000026
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-fluoroandrost-3-ene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000035
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-4-methylandrosta-3,5-diene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000032
-
(17beta)-17-[di(propan-2-yl)carbamoyl]-6-fluoroandrosta-3,5-diene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00003
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androst-3-ene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000007
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-2,4,6-triene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000007
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5,11-triene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000007
-
(17beta)-17-[di(propan-2-yl)carbamoyl]androsta-3,5-diene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00005
-
(17beta)-17-[di(propan-2-yl)carbamoyl]estra-3,5-diene-3-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000387
-
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000981
-
(17beta)-4-bromo-N-tert-butyl-3-oxoandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000437
-
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000709
-
(17beta)-N-tert-butyl-3-oxo-4-sulfanylandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000192
-
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001
-
(17beta)-N-tert-butyl-4-chloro-3-oxoandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000029
-
(17beta)-N-tert-butyl-4-cyano-3-oxoandrost-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000007
-
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000079
-
(1R,4R,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000001
-
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000012
-
(1R,4S,9aR,11aR)-4,9a,11a-trimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000001
-
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000023
-
(1R,9aR,11aR)-9a,11a-dimethyl-1-((R)-6-methylheptan-2-yl)-3,3a,3b,4,5,8,9,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridin-7(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000034
-
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000035
-
(1S,8bS,10aS)-N,N-diethyl-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,7,7a,8,8a,8b,8c,9,10,10a-hexadecahydrocyclopenta[i]cyclopropa[a]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000012
-
(1S,9aR,11aR)-1-butyl-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000004
-
(1S,9aR,11aS)-1-(cyclohexylacetyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000045
-
(1S,9aR,11aS)-6-bromo-9a,11a-dimethyl-7-oxo-N-(tricyclo[3.3.1.13,7]dec-1-yl)-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000021
-
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000097
-
(1S,9aR,11aS)-6-bromo-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000006
-
(1S,9aR,11aS)-6-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000009
-
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000051
-
(1S,9aR,11aS)-6-chloro-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000001
-
(1S,9aR,11aS)-9a,11a-dimethyl-1-nonanoyl-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[i]phenanthridin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000009
-
(1S,9aR,11aS)-9a,11a-dimethyl-N-(2-methylpropyl)-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000023
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00018
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000057
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000013
-
(1S,9aR,11aS)-N,N-diethyl-5,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000039
-
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00004
-
(1S,9aR,11aS)-N,N-diethyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000015
-
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00075
-
(1S,9aR,11aS)-N,N-diethyl-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000013
-
(1S,9aR,11aS)-N-(4,4'-di-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000046
-
(1S,9aR,11aS)-N-(4-tert-butylbiphenyl-3-yl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000042
-
(1S,9aR,11aS)-N-(5-bromo-2-tert-butylphenyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000004
-
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
(1S,9aR,11aS)-N-(dicyclohexylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000036
-
(1S,9aR,11aS)-N-(diphenylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.00003
-
(1S,9aR,11aS)-N-(diphenylmethyl)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000014
-
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000012
-
(1S,9aR,11aS)-N-tert-butyl-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000068
-
(1S,9aR,11aS)-N-[1-(4-chlorophenyl)cyclobutyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000004
-
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000088
-
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00000012
-
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000018
-
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000014
-
(1S,9aS,11aS)-N,N-diethyl-8,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,7,9a,9b,10,11,11a-dodecahydro-1H-cyclopenta[i]phenanthridine-1-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00058
-
(20E)-20-(hydroxyimino)pregn-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00163
-
(20E)-20-(hydroxyimino)pregn-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0003
-
(21E)-21-(hydroxyimino)pregn-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00195
-
(21E)-21-(hydroxyimino)pregn-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000033
-
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000036
-
(22R,S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000005
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
-
pH not specified in the publication, temperature not specified in the publication
0.000005
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (2-fluorophenyl)acetate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000007
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl (3-fluorophenyl)acetate
-
pH not specified in the publication, temperature not specified in the publication
0.00031
-
(2R,3R,10aR,12aS)-2,10a,12a-trimethyl-1,8-dioxo-3-phenyl-1,2,3,4,4a,4b,8,9,10,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl phenylacetate
-
pH not specified in the publication, temperature not specified in the publication
0.0000018
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000014
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00001
-
(3beta)-6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000007
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorophenyl)acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000006
-
(4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]phenyl)acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000049
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl 4-bromobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.000013
-
(4alpha,5alpha)-3,20-dioxo-4,5-epoxypregnan-17-yl benzoate
-
pH not specified in the publication, temperature not specified in the publication
0.000006
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0014
-
(4aR,10bR)-4,10b-dimethyl-8-[(E)-2-phenylethenyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000011
-
(4aR,10bR)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00001
-
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000059
-
(4aR,10bR)-8-(furan-2-yl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000035
-
(4aR,10bR)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00006
-
(4aR,10bR)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000017
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000183
-
(4aR,10bR)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinoline-3(2H)-thione
P18405
pH not specified in the publication, temperature not specified in the publication
0.000008
-
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.01
-
(4aR,10bR)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000035
-
(4aR,10bR)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000006
-
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0013
-
(4aR,10bR)-8-[(E)-2-(isoquinolin-4-yl)ethenyl]-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000029
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000074
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.00000055
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00005
-
(4aR,5S,6aS,11aR)-N-(diphenylmethyl)-5-hydroxy-4a,6a,10-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.0000006
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000147
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000002
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000125
-
(4aR,6aR)-1,4a,6a,10-tetramethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000054
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000084
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)-10-propyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000017
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000218
-
(4aR,6aR)-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000057
-
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00033
-
(4aR,6aR)-10-ethyl-1,4a,6a-trimethyl-7-(6-methylheptan-2-yl)hexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000016
-
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000298
-
(4aR,6aR)-4a,6a,10-trimethyl-7-(6-methylheptan-2-yl)-1,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000014
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-2-methyl-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000016
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000008
-
(4aR,6aS,11aR)-1,4a,6a,10-tetramethyl-N-(2-methyl-4-oxopentan-3-yl)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000036
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000262
-
(4aR,6aS,11aR)-N-(2-cyanopropan-2-yl)-1,4a,6a,10-tetramethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00003
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00021
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000005
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000011
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000002
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000007
-
(4aR,6aS,7S)-1,4a,6a-trimethyl-2,5-dioxo-N-[2-(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000002
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000013
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000015
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00041
-
(4aR,6aS,7S)-4a,6a-dimethyl-2,5-dioxo-N-phenylhexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00005
-
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00012
-
(4aR,6aS,7S)-N,1,4a,6a-tetramethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00042
-
(4aR,6aS,7S)-N,4a,6a-trimethyl-2,5-dioxo-N-phenyl-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000006
-
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00001
-
(4aR,6aS,7S)-N-(2-chlorophenyl)-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000006
-
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
(4aR,6aS,7S)-N-[2,5-bis(trifluoromethyl)phenyl]-1,4a,6a-trimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001218
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001553
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001611
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000053
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000055
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000381
-
(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000009
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000154
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-2-oxo-N-(4,4,4-trifluoro-3-oxobutan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001553
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001554
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000227
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000381
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001218
-
(4aR,6aS,7S,11aR)-4a,6a-dimethyl-N-(3-methylbutanoyl)-2-oxo-N-(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000055
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000212
-
(4aR,6aS,7S,11aR)-N-(3,3-dimethylpentanoyl)-1,4a,6a-trimethyl-N-(2-methylbutan-2-yl)-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000001
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000033
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-1,4a,6a-trimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.0000016
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000074
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000039
-
(4aR,6aS,7S,11aR)-N-(diphenylmethyl)-4a,6a-dimethyl-2,5-dioxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000041
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000083
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.000212
-
(4aR,6aS,7S,11aR)-N-cyclohexyl-N-(cyclohexylacetyl)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000005
-
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000081
-
(4aR,6aS,7S,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000019
-
(4aS,6aS,7S,11aR)-4a,6a-dimethyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[5,4-f]isoquinolin-7-ol
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000004
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N,N-diphenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000246
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-phenyl-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.0000056
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-2-oxo-N-[2-(trifluoromethyl)phenyl]-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000252
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
P18405
pH not specified in the publication, temperature not specified in the publication
0.00035
-
(4aS,6aS,7S,11aS)-4a,6a-dimethyl-7-[methyl(phenyl)carbamoyl]-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinolinium
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00012
-
(4aS,6aS,7S,11aS)-N,N-di(1H-indol-1-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000002
-
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.000014
-
(4aS,6aS,7S,11aS)-N-(biphenyl-3-yl)-4a,6a-dimethyl-2-oxo-2,3,4,4a,5,6,6a,7,8,9,9a,10,11,11a-tetradecahydro-1H-indeno[4,5-h]isoquinoline-7-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000000063
-
(5alpha,6alpha)-20-oxo-5,6-epoxypregn-16-en-3-yl acetate
-
pH not specified in the publication, temperature not specified in the publication
0.0000017
-
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000003
-
(5alpha17beta)-17-N,N-diethylcarbamoyl-4-methyl-4-aza-5-androstan-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000174
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000477
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000036
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000103
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000765
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethyl-1,2,3,3a,3b,4,5,5a,6,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000401
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0022
-
(5aR,9aR,11aS)-1-(3,3-dimethylbutanoyl)-9a,11a-dimethylhexadecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.012
-
(6aR,7S,9aR,11aS)-7-hydroxy-1,9a,11a-trimethylhexadecahydro-2H-indeno[5,4-f]quinolin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.015
-
(6aS,10aS,12aS)-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinoline-2,8-dione
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.004
-
(6aS,8S,10aS,12aS)-8-hydroxy-1,10a,12a-trimethylhexadecahydronaphtho[2,1-f]quinolin-2(1H)-one
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000279
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.002
-
(7aS,8S,12aR)-7a-methyl-8-(phenylamino)-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000247
-
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000913
-
(7aS,8S,12aR)-8-[benzyl(phenyl)amino]-7a-methyl-5a,6,7,7a,8,9,10,10a,10b,11,12,12a-dodecahydrocyclopenta[f]pyrido[1,2-a]quinolin-2(1H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00046
-
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001134
-
(8a,9b,10x,14x)-N-tert-butyl-3-oxoestr-4-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.04
-
(8R,9aS,11aS)-1,9a,11a-trimethyl-2-oxo-N,N-di(propan-2-yl)hexadecahydro-1H-indeno[5,4-f]quinoline-8-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000052
-
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.007
-
(9aR,11aS)-1-(3,3-dimethylbutanoyl)-6,9a,11a-trimethyl-1,2,3,3a,3b,4,6,8,9,9a,9b,10,11,11a-tetradecahydro-7H-indolo[5,4-f]quinolin-7-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000017
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
-
pH not specified in the publication, temperature not specified in the publication
-
0.0000046
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]-butyric acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
-
0.0000017
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
-
pH not specified in the publication, temperature not specified in the publication
-
0.0000046
-
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
-
0.0065
-
1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000273
-
1-cyclopropyl-3-ethyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000005
-
1-cyclopropyl-3-methyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000023
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000013
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000115
-
1-cyclopropyl-3-phenyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.002477
-
1-methyl-5-phenylpiperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000107
-
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000617
-
1-methyl-5-[4-[(E)-2-phenylethenyl]phenyl]piperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000302
-
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000579
-
1-methyl-5-[4-[(E)-phenyldiazenyl]phenyl]piperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00011
-
17-hydroxypregna-4,6-diene-3,20-dione
-
pH not specified in the publication, temperature not specified in the publication
0.0003
-
17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000017
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000019
-
17beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5alpha-androstan-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000318
-
17beta-N,N-diethylcarboxy-6-azaandrost-4-en-3-one
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
-
0.0000024
-
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000041
-
17beta-N-(2,5-bis(trifluoromethyl)-phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000105
-
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000582
-
2-methyl-N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00049
-
2-oxo-8-(prop-2-en-1-yl)-2H-chromen-7-yl benzoate
P18405
pH not specified in the publication, temperature not specified in the publication
0.00005
-
3,20-dioxopregna-4,6-dien-17-yl (4-bromophenyl)carbamate
-
pH not specified in the publication, temperature not specified in the publication
0.000031
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00037
-
3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00009
-
3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.000026
-
3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.000063
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00036
-
3,20-dioxopregna-4,6-dien-17-yl benzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00001
-
3,20-dioxopregna-4,6-dien-17-yl phenylcarbamate
-
pH not specified in the publication, temperature not specified in the publication
0.0000242
-
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000053
-
3-butyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000055
-
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino] phenoxy)benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00001
-
3-chloro-4-(4-[N-(4-phenoxybenzyl)amino]phenoxy)benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000073
-
3-chloro-4-([1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
-
0.0000053
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000046
-
3-chloro-4-([1-(4-phenoxybenzyl)indolin-5-yl]oxy)benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.000073
-
3-chloro-4-[(1-(4-phenoxybenzoyl)-1H-indol-5-yl]oxy)benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
-
0.0000032
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000315
-
3-cyclohexyl-1-cyclopropyl-1-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]urea
P18405
pH not specified in the publication, temperature not specified in the publication
0.000071
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3',5'-di(propan-2-yl)biphenyl-4-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000098
-
4'-[2-[di(propan-2-yl)amino]-2-oxoethoxy]-3'-fluoro-5'-nitrobiphenyl-4-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00513
-
4,4a,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000137
-
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000067
-
4-(1-benzyl-1H-indol-5-yl)benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000096
-
4-(2-[1-(4,4'-dipropylbenzhydryl)indole-5-carboxamido]phenoxy)butyric acid
-
pH not specified in the publication, temperature not specified in the publication
0.00084
-
4-(3-(4-(N-methylacetamido)phenyl) pentan-3-yl) phenyldibenzylcarbamate
P18405
pH not specified in the publication, temperature not specified in the publication
0.00001
-
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0063
-
4-(3-[[2,2-bis(4-chlorophenyl)-1,3-benzodioxol-5-yl]carbonyl]-2-methyl-1H-indol-1-yl)butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000005
-
4-(4-benzoylphenoxy)benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000087
-
4-(biphenyl-4-yloxy)-2-chlorobenzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000067
-
4-(biphenyl-4-yloxy)-2-fluorobenzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000056
-
4-(biphenyl-4-yloxy)-3-methoxybenzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000045
-
4-cyanoprogesterone
-
pH not specified in the publication, temperature not specified in the publication
0.00005
-
4-cyanoprogesterone
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000021
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000021
-
4-[(1-benzyl-1H-indol-5-yl)oxy]-3-chlorobenzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.000005
-
4-[1-(6,6-dimethyl-6H-dibenzo[b,d]pyran-3-yl)methylindol-3-yl]-butyric acid
-
pH not specified in the publication, temperature not specified in the publication
0.0000379
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00005
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00034
-
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000004
-
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00004
-
4-[3-(4-[(1R)-1-[4-(2-methylpropyl)phenyl]ethoxy]benzoyl)-1H-indol-1-yl]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000023
-
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000025
-
4-[3-([(2R)-2-methyl-2-[4-(2-methylpropyl)phenyl]-1,3-benzodioxol-5-yl]carbonyl)-1H-indol-1-yl]butanoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000019
-
4-[3-[3-[bis (4-isobutylphenyl)methyl amino] benzoyl]-lH-indol-l-yl] butyric acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000019
-
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000042
-
4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-lH-indol-l-yl]butyric acid
-
pH not specified in the publication, temperature not specified in the publication
0.00001
-
4-[4-(4-methylbenzoyl)phenoxy]benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00038
-
4-[4-(tricyclo[3.3.1.13,7]dec-2-ylcarbamoyl)phenoxy]benzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00029
-
4-[[1-(2-propylpentanoyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00054
-
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00069
-
4-[[1-(biphenyl-4-ylcarbamoyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.000011
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]-3-fluorobenzoic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00006
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00008
-
4-[[1-(dicyclohexylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00037
-
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.00344
-
4-[[1-(diphenylacetyl)piperidin-4-ylidene]methyl]benzoic acid
-
pH not specified in the publication, temperature not specified in the publication
0.0000006
-
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0000058
-
5-(2-ethyl-3-[3-[(4-hexylundecyl)amino]benzoyl]-1H-pyrrol-1-yl)pentanoate
-
pH not specified in the publication, temperature not specified in the publication
0.00169
-
5-(4-chlorophenyl)-1-methylpiperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0123
-
5-(4-chlorophenyl)-1-methylpiperidin-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00336
-
5-(4-chlorophenyl)-1-methylpiperidine-2-thione
P18405
pH not specified in the publication, temperature not specified in the publication
0.00000242
-
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001
-
5-bromo-N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]pentanamide
P18405
about, pH not specified in the publication, temperature not specified in the publication
0.0000037
-
6,20-dioxopregn-4-en-3-yl 4-fluorobenzoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000018
-
6,20-dioxopregna-4,16-dien-3-yl 3-bromopropanoate
-
pH not specified in the publication, temperature not specified in the publication
0.000014
-
6,20-dioxopregna-4,16-dien-3-yl 3-chloropropanoate
-
pH not specified in the publication, temperature not specified in the publication
0.00001
-
6,20-dioxopregna-4,16-dien-3-yl 3-iodopropanoate
-
pH not specified in the publication, temperature not specified in the publication
0.000003
-
6,20-dioxopregna-4,16-dien-3-yl 4-fluorobenzoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000004
-
6,20-dioxopregna-4,16-dien-3-yl 4-methylbenzoate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000000065
-
6,20-dioxopregna-4,16-dien-3-yl acetate
-
pH not specified in the publication, temperature not specified in the publication
0.00000007
-
6,20-dioxopregna-4,16-dien-3-yl benzoate
-
pH not specified in the publication, temperature not specified in the publication
0.0000143
-
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000033
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000033
-
6-bromo-3,20-dioxopregna-4,6-dien-17-yl acetate
-
pH not specified in the publication, temperature not specified in the publication
0.00097
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-bromobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00099
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-chlorobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00093
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl 4-fluorobenzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00092
-
6-chloro-3,20-dioxopregna-4,6-dien-17-yl benzoate
-
pH not specified in the publication, temperature not specified in the publication
0.00075
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00081
-
6-[3-(N,N-dicyclohexylaminocarbonyl)phenyl]-3,4-dihydro-naphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0002
-
6-[4-(N,N-diisopropylamino-carbonyl)phenyl]naphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00068
-
6-[4-[di(propan-2-yl)carbamoyl]phenyl]-3,4-dihydronaphthalene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.0013
-
7-[(3-methylbut-2-en-1-yl)oxy]-2H-chromen-2-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000152
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00034
-
7-[(E)-2-phenylethenyl]-9,10-dihydrophenanthrene-2-carboxylic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00099
-
8-allyl-7-hydroxycoumarin
P18405
pH not specified in the publication, temperature not specified in the publication
0.00006
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.02
-
8-chloro-1,2,5,6,6a,7,8,9,10,10a-decahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000058
-
8-chloro-1,2,5,6,7,8,9,10-octahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000049
-
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00046
-
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000204
-
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000459
-
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000085
-
8-chloro-4,6-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00003
-
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000076
-
8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.000176
-
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
P18405
pH not specified in the publication, temperature not specified in the publication
0.00003
-
epristeride
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.0046
-
estra-4,9(11)-diene-3,17-dione
P18405
pH not specified in the publication, temperature not specified in the publication
0.000013
-
ethyl 4-[2-[([1-[bis(4-propylphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl)amino]phenoxy]butanoate
-
pH not specified in the publication, temperature not specified in the publication
0.000003
-
finasteride
P18405
type II 5alpha-reductase, pH not specified in the publication, temperature not specified in the publication
0.000008
-
finasteride
-
37C
0.000051
-
finasteride
-
pH 7.4, 37C, recombinant His-tagged enzyme
0.000055
-
finasteride
-
37C
0.0003
-
finasteride
P18405
type I 5alpha-reductase, pH not specified in the publication, temperature not specified in the publication
0.0000032
-
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
pH not specified in the publication, temperature not specified in the publication
0.00015
-
methyl(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000018
-
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000039
-
N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.00000235
-
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0001
-
N-(3,3-dimethylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
above, pH not specified in the publication, temperature not specified in the publication
0.0000022
-
N-(3-methylbutan-2-yl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000219
-
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0001
-
N-(3-methylbutyl)-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
above, pH not specified in the publication, temperature not specified in the publication
0.00000544
-
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001
-
N-(4-methoxycyclohexyl)-2-methyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]propanamide
P18405
about, pH not specified in the publication, temperature not specified in the publication
0.0000026
-
N-butyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000957
-
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.000014
-
N-heptyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000169
-
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000184
-
N-octyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000018
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000177
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.001
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]butanamide
P18405
about, pH not specified in the publication, temperature not specified in the publication
0.00000091
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0001
-
N-pentyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
above, pH not specified in the publication, temperature not specified in the publication
0.00000293
-
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000038
-
N-phenyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]benzamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000051
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a,10-tetramethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00000305
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
pH not specified in the publication, temperature not specified in the publication
0.0001
-
N-propyl-N-[(4aR,6aS,7S,11aR)-1,4a,6a-trimethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinolin-7-yl]formamide
P18405
above, pH not specified in the publication, temperature not specified in the publication
0.000051
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.00006
-
N-[1,1,1-trifluoro-2-oxobut-3-yl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide
-
pH not specified in the publication, temperature not specified in the publication
0.00000085
-
pregna-4,16-diene-3,6,20-trione
-
pH not specified in the publication, temperature not specified in the publication
0.0000001
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
below, pH not specified in the publication, temperature not specified in the publication
0.00000016
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
pH not specified in the publication, temperature not specified in the publication
0.0000069
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
pH not specified in the publication, temperature not specified in the publication
0.00002
-
tricyclo[3.3.1.13,7]dec-2-yl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylate
P18405
pH not specified in the publication, temperature not specified in the publication
0.000005
-
[3-methyl-4-(4-phenoxybenzoyl)phenyl]acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.000023
-
[4-(4-phenoxybenzoyl)phenyl]acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication
0.00006
-
[4-(biphenyl-4-yloxy)phenyl]acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication; pH not specified in the publication, temperature not specified in the publication
0.000027
-
[4-[4-(4-bromophenoxy)benzoyl]phenyl]acetic acid
P18405
pH not specified in the publication, temperature not specified in the publication
SPECIFIC ACTIVITY [µmol/min/mg]
SPECIFIC ACTIVITY MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
additional information
-
-
-
additional information
-
-
method development for exact quantitative detection of mRNA levels of isozymes by RT-PCR and capillary electrophoresis, overview
pH OPTIMUM
pH MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
5
5.5
P31213
SRD5alpha2 has a sharp pH-optimum
5.5
-
C7T2J7, C7T2J8
recombinant Srd5a2
5.5
-
-
assay at
5.5
-
-
type II isozyme
6
8.5
P31213
SRD5alpha1 has a broad pH range
6.5
8
C7T2J7, C7T2J8
recombinant Srd5a1
6.5
9
-
type I isozyme
6.9
-
P31213
SRD5alpha3
7.2
-
P18405
assay at; assay at
7.4
-
-
assay at
8
9
-
reaction with 1-androstene-3,17-dione and N,N,N,N-tetramethyl-1,4-phenylenediamine
pH RANGE
pH RANGE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
7
9
-
pH 7.0: about 40% of maximal activity, pH 8.0-9.0: maximal activity, reaction with Delta1-androstene-3,17-dione and N,N,N,N-tetramethyl-1,4-phenylenediamine
TEMPERATURE OPTIMUM
TEMPERATURE OPTIMUM MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
37
-
-
assay at
37
-
-
-
40
-
-
reaction with 1-androstene-3,17-dione and N,N,N,N-tetramethyl-1,4-phenylenediamine
TEMPERATURE RANGE
TEMPERATURE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
25
50
-
25C: about 50% of maximal activity, 50C: about 20% of maximal activity, reaction with N,N,N,N-tetramethyl-1,4-phenylenediamine
SOURCE TISSUE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
SOURCE
-
abnormally high expression of isoform 2 enzyme in male and female
Manually annotated by BRENDA team
-
enzyme-positive prostate cancer cell line, enzyme can be lost in long-term culture
Manually annotated by BRENDA team
-
adult, isozymes 5alpha-R1 and 5alpha-R2
Manually annotated by BRENDA team
-
enzyme isoform I and 3alpha-hydroxysteroid dehydrogenase colocalize in hippocampal and olfactory bulb glutamatergic principal neurons and in some output neurons of amygdala and thalamus. Neither enzyme is expressed in S100beta- or glial fibrillary acidic protein-positive glial cells. Both enzymes are significantly expressed in principal GABAergic output neurons
Manually annotated by BRENDA team
-
enzyme activity in both sexes
Manually annotated by BRENDA team
-
prefrontal, expression of isozymes 5alpha-R1 and 5alpha-R2
Manually annotated by BRENDA team
-
SRD5alpha3 occurs in whole embryo and larvae bodies
Manually annotated by BRENDA team
C7T2J7, C7T2J8
Srd5a2
Manually annotated by BRENDA team
P18405
from all areas
Manually annotated by BRENDA team
C7T2J7, C7T2J8
both Srd5a1 and Srd5a2 are expressed without clear differences between males and females; both Srd5a1 and Srd5a2 are expressed without clear differences between males and females
Manually annotated by BRENDA team
P18405
epidermal and follicular
Manually annotated by BRENDA team
-
SRD5alpha3 occurs in whole embryo and larvae bodies
Manually annotated by BRENDA team
-
activity in female liver is about 4times higher than in male liver
Manually annotated by BRENDA team
-
from female intact and ovariectomized rats, predominantly isozyme 5alpha-R1
Manually annotated by BRENDA team
C7T2J7, C7T2J8
Srd5a1
Manually annotated by BRENDA team
-
enzyme-positive prostate cancer cell line, enzyme can be lost in long-term culture
Manually annotated by BRENDA team
-
no expression of enzyme isoform II
Manually annotated by BRENDA team
-
predominantly isozyme 5alpha-R2
Manually annotated by BRENDA team
-
ventral prostate tissue
Manually annotated by BRENDA team
-
high expression level of Srd5a2
Manually annotated by BRENDA team
P31213
SRD5alpha2 is mainly associated with androgen target tissues, e.g. prostate
Manually annotated by BRENDA team
P18405
the enzyme is a system of two membrane bound NADPH-dependent enzymes at the level of prostatic stromal and basal cells
Manually annotated by BRENDA team
-
prostate cancer cell lines
Manually annotated by BRENDA team
-
prostate cancer cell
Manually annotated by BRENDA team
Rattus norvegicus Wistar
-
-
-
Manually annotated by BRENDA team
-
predominantly isozyme 5alpha-R1
Manually annotated by BRENDA team
-
dermal papillae from the lower abdominal region
Manually annotated by BRENDA team
-
high expression level of Srd5a2
Manually annotated by BRENDA team
P31213
SRD5alpha1 is mostly high in none androgen target tissues, e.g. skin
Manually annotated by BRENDA team
P18405
genital; sebaceous glands
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
P18405
the enzyme is a system of two membrane bound NADPH-dependent enzymes at the level of prostatic stromal and basal cells; the enzyme is a system of two membrane bound NADPH-dependent enzymes at the level of prostatic stromal and basal cells
Manually annotated by BRENDA team
PDB
SCOP
CATH
ORGANISM
Rhodococcus sp. (strain RHA1)
Rhodococcus sp. (strain RHA1)
SUBUNITS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
?
-
x * 58100, calculation from nucleotide sequence; x * 60000, SDS-PAGE
Crystallization/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
to 1.6 A resolution, structure reveals three conserved residues, Y319, Y466, and S468 in a pocket near the isoalloxazine ring system of the FAD co-factor. Crystal structure with bound product 4-androstene-3,17-dione shows that residue S468 is in a position in which it can serve as the base abstracting the 4beta-proton from the C4 atom of the substrate. S468 is assisted by Y319, which possibly is involved in shuttling the proton to the solvent. Y466 is at hydrogen bonding distance to the C3 oxygen atom of the substrate and can stabilize the keto-enol intermediate occurring during the reaction. The FAD N5 atom is in a position to be able to abstract the 5alpha-hydrogen of the substrate as a hydride ion
Q0S4Q9
Purification/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
recombinant His-tagged SRD5A2 from CHO cells by nickel affinity chromatography and anion exchange chromatography
-
Cloned/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group. SRD5alpha1 is located on chromosome 5p15 whereas SRD5alpha2 is located on 2p22, and SRD5alpha3 is located at 4q12
-
expression in Escherichia coli JM109 carrying pXE25, activity is maximal 18times higher than the activity expressed by induced cells of Comamonas testosteroni. Overexpression in Pseudomonas putida KT2440 using pMMB208 as expression vector, activity is maximaly 264times higher than the activity expressed by induced cells of Comamonas testosteroni
-
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group
-
gene SRD5A2, DNA and amino acid sequence analysis in 6 Korean patients with 5alpha-reductase type 2 deficiency, overview
-
gene SRD5A2, DNA and amino acid sequence determination, expression of His-tagged enzyme in Escherichia coli strain DH5alpha and in CHO cells
-
gene SRD5A2, genotyping of 114 prostate cancer patients and 144 healthy control males for single-nucleotide polymorphisms, A49T and V89L, overview. Individuals with LL genotype show reduction in the progression to a higher tumor stage
P31213
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group. SRD5alpha1 is located on chromosome 5p15 whereas SRD5alpha2 is located on 2p22, and SRD5alpha3 is located at 4q12
P31213
transient expression of pTRE-5alphaR1 in LNGK-9 PCa cells. Addition of testosterone increases growth of pTRE-5alphaR1 transfectants by 54.1% over cells grown in the absence of testosterone, compared to 25.0% in control cells. Testosterone also increases secretion of prostate-specific antigen 17fold in the 5alphaR1-transfected cells
P18405
Srd5a1 DNA and amino acid sequence determination and analysis, expression of Srd5a2 in HEK-293 cells, real-time quantitative RT-PCR expression analysis with higher mRNA levels for Srd5a1 than for Srd5a2; Srd5a2 DNA and amino acid sequence determination and analysis, expression of Srd5a2 in HEK-293 cells, real-time quantitative RT-PCR expression analysis with higher mRNA levels for Srd5a1 than for Srd5a2
C7T2J7, C7T2J8
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group
-
sterol regulatory element binding proteins, SREBPs, regulate expression of Srd5a2. 293T cells are transfected with the Srd5a2 promoter-luciferase reporter and flag-pCDNA3.1+ SREBP-2 plasmids. SREBP-2 binds to the promoter for Srd5a2
-
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group
-
quantitative expression analysis of isozymes 5alpha-R1 and 5alpha-R2 in brain
-
Xenopus oocytes are able to synthesize the enzyme, directly by microinjected poly(A)+ RNA prepared from female and male rat liver
-
phylogenetic analysis of SRD5alpha, overview. SRD5alpha subfamilies include, not only the well-known SRD5alpha type 1, type 2 and type 3, but also the synaptic glycoprotein (GPSN2)/trans-2,3-enoly-CoA reductase group
-
EXPRESSION
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
17beta-estradiol administered to spayed females induces the up-regulation of Srd5a2 mRNA levels
C7T2J7, C7T2J8
Srd5a2 is induced in livers and prostate from mice fed a chow diet supplemented with lovastatin plus ezitimibe, which increases the activity of nuclear SREBP-2, induction of Srd5a2 through SREBP-2, SREBP-2 binds to the promoter for Srd5a2
-
ENGINEERING
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
A207D
-
the mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
A49T
-
naturally occuring mutation of isoform 2, associated with significantly higher sperm concentration than wild-type
A49T
P31213
naturally occuring mutation, the mutation is associated with a higher pTNM stage and and elevated Gleason grade. The allelic frequencies of the A49T variant, with 33% controls and 45% prostate cancer cases, are the highest reported worldwide. The polymorphism influences the risk of developing prostate cancer
C133G
-
the mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
G196S
-
the mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
G203S
-
naturally occuring mutation of SRD5A2 involved in the SRD deficiency syndrome
G34W
-
the mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
R246Q
-
frequent naturally occuring mutation of SRD5A2 involved in the SRD deficiency syndrome
V89L
-
naturally occuring mutation of isoform 2, correlates with significantly higher proportion of progressive motile spermatozoa than wild-type
V89L
P31213
naturally occuring mutation. The polymorphism influences the risk of developing prostate cancer
W53X
-
the nonsense mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
Y235F
-
the mutation is associated with the occurrence of steroid 5alpha-reductase deficiency
S468A
Q0S4Q9
no residual activity
S468T
Q0S4Q9
about 65% of wild-type catalytic efficiency
W136A
Q0S4Q9
no residual activity
W136F
Q0S4Q9
about 40% of wild-type catalytic efficiency
Y319F
Q0S4Q9
no residual activity
Y466A
Q0S4Q9
no residual activity
Y466F
Q0S4Q9
no residual activity
L55Q
-
the naturally occuring homozygote point mutation causes SRD5A2 deficiency and leads to leading to an impaired conversion of testosterone to 5alpha-dihydrotestosterone, and thus to predominantly female phenotype at 3 days of age with ambiguous external genitalia: testes palpable in the extended labia resembling a scrotum bipartitum, micropenis with hypospadias and lack of an introitus vaginae but a perineal dimple in accordance with steroid 5alpha-reductase deficiency type III
additional information
-
two Korean sisters with male pseudohermaphroditism, showing a homozygous deletion of the thymine at nucleotide position c.655, leading to a frameshift mutation predicted to result in abnormally long protein with an extended termination signal
additional information
-
detection of mutations of gene SRD5A2 of Korean SRD deficiency patients: p.Q6X located in exon 1, p.G203S and c.655delT both located in exon 4, and p.R246Q located in exon 5, which is the most frequently identified mutation, and c.655delT specifically found in Korean patients, overview. 5alpha-Reductase type 2 deficiency, caused by mutations in the SRD5A2 gene, leads to an autosomal recessive disorder of sex differentiation, DSD, in 46,XY individuals. The phenotypes of newborn 46,XY DSD with partial androgen insensitivity syndrome or 17beta-hydroxysteroid dehydrogenase deficiency may be indistinguishable from the phenotype of 5alpha-reductase type 2 deficiency
APPLICATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
medicine
-
in recurrent prostate cancer, expression levels and isozyme activity shifts from isoform II towards isoform I. Immunostaining shows higher expression of isoform I than isoform II in recurrent prostate cancer, androgen-stimulated benign prostate, and in androgen-stimulated prostate cancers. Activity of isoform I is 3.7fold higher than isoform II in recurrent prostate cancers
medicine
-
in patients with hirsutism, positive correlation of enzyme isoforms 1 and 2 mRNA and concentration of free serum testosterone in dermal papillae from lower abdominal region
medicine
-
two Korean sisters with male pseudohermaphroditism, showing a homozygous deletion of the thymine at nucleotide position c.655, leading to a frameshift mutation predicted to result in abnormally long protein with an extended termination signal
medicine
-
enzyme isoform 2 gene variants are associated with sperm concentration and motility, but not with epidymal and accessory sex gland markers
medicine
-
therapeutic potential of enzyme inhibitors MK386 and MK906 to reduce growth and progression of prostatic cancer
medicine
-
analysis of single-type nucleotide polymorphisms in isoforms SRD5A1 and SRD5A2. Haplotypes within both genes are associated with homocystic ovary syndrome risk. V89L variant of isoform SRD5A2 is associated with protection against homocystic ovary syndrome. Haplotypes in SRD5A1 are also associated with the degree of hirsutism in affected women
medicine
-
treatment of patients with clinically localized prostate cancer with enzyme inhibitor dutasteride before radical prostatectomy. Treatment with dutasteride is associated with reductions in serum and intraprostatic dihydrotestosterone of more than 90%, and a decrease in total prostate and tumor volumes. No effect of dutasteride is noted on Gleason grade
medicine
-
inhibitor Strogen forte extract can be used for treatment of benign prostatic hyperplasia